What To Know
- In adult participants, the performance with cross-validation from the AI model for identification of non-healing burn regions showed 92% accuracy, an improvement on the previously reported accuracy of 91% for the DeepView® Wound Imaging Solution in early healing assessment of adults.
- Spectral MD is also proud to announce their most recent publication in the Journal of Burn Care and Research, “Use of 816 Consecutive Burn Wound Biopsies to Inform a Histologic Algorithm for Burn Depth Categorization,”.
Spectral MD, a predictive analytics company that develops proprietary AI algorithms and optical technology to hopefully provide faster and more accurate treatment decisions in wound care, is proud to announce three scientific presentations at Southern Region Burn Conference held in New Orleans, Louisiana, from Nov. 4-7, 2021.
The researchers presented recent findings using Spectral MD’s DeepView® multispectral imaging technology and artificial intelligence to improve the assessment of burn wounds.
The results of the first multi-center study using Spectral MD’s burn imaging technology include 124 adult and pediatric participants. In adult participants, the performance with cross-validation from the AI model for identification of non-healing burn regions showed 92% accuracy, an improvement on the previously reported accuracy of 91% for the DeepView® Wound Imaging Solution in early healing assessment of adults. In pediatric patients, the AI performance showed 88% accuracy, underlining how the technology is responding with significant reliability to variability in the study population.
The Southern Region Burn Conference – SMA is one of the largest scientific burn conferences held each year with hundreds in attendance. The titles of the presentations related to Spectral MD’s work and the presenters were as follows:
Dr. James H. Holmes IV presented, “Initial Experience Using Artificial Intelligence for the Assessment of Pediatric Burn Depth.”
Dr. Herbert Phelan reported on, “Iterative Refinement of a Histologic Algorithm for Burn Depth Categorization Based on 1142 Consecutive Burn Wound Biopsies.”
Dr. Jeffrey Carter presented, “Rise of the (Learning) Machines: Artificial Intelligence for the Assessment of Adult Thermal Burns.”
Spectral MD is also proud to announce their most recent publication in the Journal of Burn Care and Research, “Use of 816 Consecutive Burn Wound Biopsies to Inform a Histologic Algorithm for Burn Depth Categorization,” led by author Dr. Herbert Phelan. The study was originally presented at the 2021 American Burn Association Conference and details the years of work performed by Spectral MD and clinical colleagues to characterize burn depth using histologic parameters. Dr. Jeffrey Carter stated, “This is an exciting time for Spectral MD and the burn community as we open new sites for the next study phase and begin to share the great results we have already established.”
“This meeting marks the first time we present results from a multi-center study with the DeepView® burn assessment technology,” said Jeffrey Thatcher, Chief Scientist of Spectral MD. “This study, involving participants aged 7 months and older, was critical toward our goal of understanding the use of this technology for both adults and children with burn injuries.”
Spectral MD has received total funding commitments from the Biomedical Advanced Research and Development Authority (BARDA) to date of approximately $93 million. In 2021, Spectral MD received $20.6 million in March 2021, with follow-up funding of $18.8 million in September 2021. The funding will be used to expand the current clinical training study of Spectral MD’s DeepView® Wound Imaging System for burn wound healing assessment.
The funding and technical development of the DeepView burn assessment technology has been supported in whole by the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response under contract number 75A50119C00033.
Spectral MD devices are in various stages of research and development including pre-clinical testing and clinical investigations. At this time, no SMD devices have received marketing authorization and therefore, are not available for sale in the U.S.A.